Morris James LLP is now accepting cases on behalf of patients who suffered serious vision loss after taking GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and related drugs.
Our mass torts attorneys are investigating claims that the manufacturers of these widely prescribed diabetes and weight-loss medications failed to warn patients about the risk of NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy), a serious and often permanent eye condition.
These cases focus exclusively on vision and optic nerve injuries. They are separate from the Ozempic stomach and gastroparesis lawsuits you may have seen in the news. If you experienced vision problems while taking a GLP-1 medication, you may have an independent legal claim worth pursuing.
“People taking these medications had a right to know about the risk of losing their vision. They weren't given that chance, and we intend to hold the manufacturers responsible,”
Keith Donovan, Managing Partner at Morris James
What Is NAION?
NAION is caused by a sudden interruption of blood flow to the optic nerve, leading to rapid, painless, and often irreversible vision loss. Recent scientific studies have found that patients taking semaglutide significantly more likely to develop NAION than non-users — a risk that the drug manufacturers did not adequately disclose.
Do You Have a Claim?
You may be eligible to bring a legal claim if you were prescribed a GLP-1 medication and subsequently developed NAION (non-arterial anterior ischemic optic neuropathy). Pre-existing diabetes does not disqualify you.
Morris James attorneys Keith E. Donovan and Matthew R. Fogg are leading this litigation. We accept cases nationwide and handle them on a contingency fee basis — you pay nothing unless we recover compensation for you.
Legal filing deadlines vary by state and may already be running. If you or a loved one lost vision while taking Ozempic, Wegovy, or another GLP-1 drug, we want to hear from you. Contact us online or by calling 302.655.2599 for a free, confidential consultation.
